3-deazaneplanocin A is a promising therapeutic agent for ovarian cancer cells

6Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

methyltransferase inhibitor, disrupts polycomb-repressive complex 2 (PRC2), and induces apoptosis, while inhibiting proliferation and metastasis, in cancer cells, including acute myeloid leukemia, breast cancer and glioblastoma. However, little is known about effects of DZNep on ovarian cancer cells. Materials and Methods: We here therefore studied DZNep-treated A2780 ovarian cancer cells in vitro. Proliferation of ovarian cancer cells under treatment of DZNep was assessed by MTT and apoptosis by flow cytometry. Cell wound healing was applied to detect the migration. Finally, we used q-PCR to assess the migration-related gene, E-cadherin. Results: DZNep could inhibit the proliferation of A2780 and induce apoptosis Furthermore, it inhibited migration and increased the expression of E-cadherin (P<0.05). Conclusion: DZNep is a promising therapeutic agent for ovarian cancer cells, with potential to inhibite proliferation, induce apoptosis and decrease migration.

Cite

CITATION STYLE

APA

Shen, L., Cui, J., Pang, Y. X., Ma, Y. H., & Liu, P. S. (2013). 3-deazaneplanocin A is a promising therapeutic agent for ovarian cancer cells. Asian Pacific Journal of Cancer Prevention, 14(5), 2915–2918. https://doi.org/10.7314/APJCP.2013.14.5.2915

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free